📣 Send us your press release
Site updates every 15 minutes
Technology

Scrutiny surrounds Haemanthus as startup pursues diagnostic technology

Haemanthus, the blood-testing startup founded by Billy Evans, remains in stealth mode as analysts evaluate the company's branding choices and underlying technology.

16 November 2026
Scrutiny surrounds Haemanthus as startup pursues diagnostic technology

Haemanthus, a company developing diagnostic tools based on Raman spectroscopy, continues to operate with minimal public disclosure. The startup has reportedly raised $18.5 million to develop a system designed to analyze biological samples. While the company initially aims to process samples from pets, its long-term roadmap includes the development of a wearable device for human use.

Public interest in the company is driven by founder Billy Evans’s personal ties to Elizabeth Holmes, the disgraced founder of Theranos. Despite Haemanthus’s attempts to distance itself from the failed blood-testing giant, discrepancies in corporate messaging have fueled industry speculation regarding the company’s transparency and legitimacy.

Design professionals analyzing the firm’s wordmark—the only public brand element—note that its aesthetic choices diverge from typical biotechnology industry standards. Rather than prioritizing symbols of clinical precision or transparency, the logo utilizes elements reminiscent of heritage luxury branding. Industry observers suggest this may signal a failure to distinguish between personal branding preferences and the necessity of building institutional trust in a high-stakes medical field.

Original source: fastcompany.com